-
Published 4/10/2025
de Almeida JR, Su J, AlShenaiber A, Noroozi H, Buttner M, Goldstein DP, Hansen A, Kowalski LP, Licitra L, Mehanna H, Noel CW, Parmar A, Porceddu S, Ringash J, Rogers S, Dos Santos MA, Simon C, Truong MT, Xu W. Development, Validation, and Valuation of a Head and Neck Cancer-Specific Health Utility Instrument (HNC-8D): A Head and Neck Cancer International Group Collaborative Study. JAMA Otolaryngol Head Neck Surg. 2025 Apr 10. PMID: 40208586.
-
Published 4/6/2025
Yin J, Qureshi MM, Huang D, Truong MT, Mak KS, Yan S, Hirsch AE. Factors Associated With Early Discontinuation of Radiation Therapy: An Analysis of the National Cancer Database. Adv Radiat Oncol. 2025 Jun; 10(6):101784. PMID: 40421078.
-
Published 3/17/2025
Paes T, Buelvas Mebarak J, Magnotto JC, Stamatiades GA, Kuang Y, Paweletz CP, Laws ER, Grosek N, Carroll RS, Jeselsohn R, Mohan DR, Marcondes Lerario A, Truong MT, Bi WL, Reardon DA, Meredith DM, Kaiser UB, Abreu AP. Somatic Activating ESR1 Mutation in an Aggressive Prolactinoma. J Clin Endocrinol Metab. 2025 Mar 17; 110(4):1166-1176. PMID: 39238355.
-
Published 11/14/2024
Mell LK, Torres-Saavedra PA, Wong SJ, Kish JA, Chang SS, Jordan RC, Liu T, Truong MT, Winquist EW, Takiar V, Wise-Draper T, Robbins JR, Rodriguez CP, Awan MJ, Beadle BM, Henson C, Narayan S, Spencer SA, Powell S, Dunlap N, Sacco AG, Hu KS, Park HS, Bauman JE, Harris J, Yom SS, Le QT. Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. Lancet Oncol. 2024 Dec; 25(12):1576-1588. PMID: 39551064.
-
Published 9/6/2024
Lin Y, Qureshi MM, Batra S, Truong MT, Mak KS. Consecutive Daily Versus Every Other Day Stereotactic Body Radiation Therapy Scheduling for Stage I Non-small Cell Lung Cancer. Adv Radiat Oncol. 2024 Dec; 9(12):101625. PMID: 39524524.